Drugs / LY3938577
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06280703 | May 2024 → Oct 2026 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06132126 | Nov 2023 → Jun 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07215312 | Oct 2025 → Nov 2026 expected | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3938577 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132126 ↗ |
| Route | Subcutaneous | “LY3938577 administered Subcutaneously (SC).” NCT06132126 ↗ |